Tenofovir Disoproxil Fumarate - Product Review

This review is a summary of evidence in support of tenofovir disoproxil fumarate (Viread®) use in treatment-naïve patients with hepatitis B virus infection. Tenofovir* is registered in Australia and reimbursed on the PBS. New prescribing arrangements came into force on 1 July 2015, so that accredited GPs can now start first-line tenofovir therapy in adults with chronic hepatitis B (CHB).1 Tenofovir is also indicated for use in treatment-experienced adults with CHB; patients aged ≥12 years with CHB and compensated liver disease plus immune active disease (i.e. active viral replication, persistently raised plasma levels of alanine aminotransferase, or evidence of active inflammation); and in combination with other antiretroviral agents for the treatment of HIV-infected adults and patients aged ≥12 years.2 * Throughout this review, the prodrug tenofovir disoproxil fumarate has generally been abbreviated to tenofovir.

Independent commentary is provided by Dr David Iser MBBS (Hons) BMedSc PhD FRACP.

Please login below to download this issue (PDF)

Subscribe